Stock Events

Stock Events

Monopar Therapeutics 

€0.5650
0
+€0.00+0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
3.08
52W Low
0.258
Volume
-
Avg. Volume
19
Mkt Cap
3.78M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q1 2026
Next
-0.62
-0.54
-0.47
-0.39
Expected EPS
-0.57314763491
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-11.87MNet Income

Analyst Ratings

81.44Average Price Target
The highest estimate is 88.78.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1IY.STU. It's not an investment recommendation.
NVIDIA
8
NVDA
D-Wave Quantum
8
QBTS
Apple
7
AAPL
Microsoft
6
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences is a biopharmaceutical company that competes in developing treatments for life-threatening diseases, overlapping with Monopar's focus on severe and life-threatening diseases.
AMGEN
AMGN
Mkt Cap201.93B
Amgen is a biotech firm focusing on novel therapies, including for cancer and other serious illnesses, directly competing with Monopar's therapeutic development.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol Myers Squibb operates in the oncology space, developing cancer treatments that could compete with Monopar's cancer-focused pipeline.
Merck
MRK
Mkt Cap319.99B
Merck is known for its strong oncology portfolio, including therapies for various cancers, which competes with Monopar's cancer treatment developments.
Pfizer
PFE
Mkt Cap138.61B
Pfizer has a broad range of therapeutic products, including in oncology, which competes with Monopar's focus areas.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie has a significant presence in oncology and other serious health conditions, competing with Monopar's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals focuses on developing drugs for serious diseases, including cancer, making it a competitor to Monopar.
Novartis
NVS
Mkt Cap305.1B
Novartis is a global healthcare company with a strong emphasis on research and development in oncology, competing with Monopar's focus.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca has a significant oncology portfolio, directly competing with Monopar's cancer therapy developments.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for various diseases, including cancer, competing with Monopar's therapeutic focus.

About

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Show more...
CEO
Dr. Christopher M. Starr Ph.D.
Employees
22
Country
United States
ISIN
US61023L1089

Listings

STU
DE
1IY0.STU
STU
DE
1IY.STU
MU
DE
1IY0.MU
F
DE
1IY0.F

0 Comments

Share your thoughts

FAQ

What is Monopar Therapeutics stock price today?▼
The current price of 1IY.STU is €0.57 EUR — it has increased by +0% in the past 24 hours. Watch Monopar Therapeutics stock price performance more closely on the chart.
What is Monopar Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Monopar Therapeutics stocks are traded under the ticker 1IY.STU.
What is Monopar Therapeutics market cap?▼
Today Monopar Therapeutics has the market capitalization of 3.78M
When is the next Monopar Therapeutics earnings date?▼
Monopar Therapeutics is going to release the next earnings report on August 06, 2026.
What were Monopar Therapeutics earnings last quarter?▼
1IY.STU earnings for the last quarter are -0.39 EUR per share, whereas the estimation was -0.62 EUR resulting in a +36.21% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Monopar Therapeutics revenue for the last year?▼
Monopar Therapeutics revenue for the last year amounts to 0 EUR.
What is Monopar Therapeutics net income for the last year?▼
1IY.STU net income for the last year is -11.87M EUR.
How many employees does Monopar Therapeutics have?▼
As of July 10, 2026, the company has 22 employees.
In which sector is Monopar Therapeutics located?▼
Monopar Therapeutics operates in the Other sector.
When did Monopar Therapeutics complete a stock split?▼
Monopar Therapeutics has not had any recent stock splits.
Where is Monopar Therapeutics headquartered?▼
Monopar Therapeutics is headquartered in Wilmette, United States.